{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:08:27Z","timestamp":1792681707975,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s40265-018-1000-9","type":"journal-article","created":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T08:08:46Z","timestamp":1540368526000},"page":"1763-1767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":155,"title":["Moxetumomab Pasudotox: First Global Approval"],"prefix":"10.1007","volume":"78","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,24]]},"reference":[{"issue":"3","key":"1000_CR1","first-page":"205","volume":"16","author":"RJ Kreitman","year":"2018","unstructured":"Kreitman RJ, Arons E. Update on hairy cell leukemia. Clin Adv Hematol Oncol. 2018;16(3):205\u201315.","journal-title":"Clin Adv Hematol Oncol."},{"issue":"5","key":"1000_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","volume":"129","author":"MR Grever","year":"2017","unstructured":"Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129(5):553\u201360.","journal-title":"Blood."},{"issue":"4","key":"1000_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.beha.2015.10.015","volume":"28","author":"BM Getta","year":"2015","unstructured":"Getta BM, Park JH, Tallman MS. Hairy cell leukemia: past, present and future. Best Pract Res Clin Haematol. 2015;28(4):269\u201372.","journal-title":"Best Pract Res Clin Haematol."},{"key":"1000_CR4","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/asheducation.V2012.1.660.3798659","volume":"2012","author":"RJ Kreitman","year":"2012","unstructured":"Kreitman RJ. Immunoconjugates and new molecular targets in hairy cell leukemia. Hematology. 2012;2012:660\u20136.","journal-title":"Hematology."},{"key":"1000_CR5","unstructured":"AstraZeneca. LUMOXITI\u2122 (moxetumomab pasudotox-tdfk): US prescribing information. 2018. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761104s000lbl.pdf\n                    \n                  . Accessed 4 Oct 2018."},{"key":"1000_CR6","unstructured":"FDA. FDA approves moxetumomab pasudotox-tdfk for hairy cell leukemia [media release]. 13 Sept 2018. \n                    https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm620473.htm\n                    \n                  ."},{"issue":"3","key":"1000_CR7","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/1078-0432.CCR-08-1456","volume":"15","author":"RF Alderson","year":"2009","unstructured":"Alderson RF, Kreitman RJ, Chen T, et al. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res. 2009;15(3):832\u20139.","journal-title":"Clin Cancer Res."},{"issue":"4","key":"1000_CR8","first-page":"995","volume":"8","author":"G Salvatore","year":"2002","unstructured":"Salvatore G, Beers R, Margulies I, et al. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res. 2002;8(4):995\u20131002.","journal-title":"Clin Cancer Res."},{"issue":"20","key":"1000_CR9","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","volume":"17","author":"RJ Kreitman","year":"2011","unstructured":"Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011;17(20):6398\u2013405.","journal-title":"Clin Cancer Res."},{"issue":"8","key":"1000_CR10","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","volume":"32","author":"RJ Kreitman","year":"2018","unstructured":"Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia. Leukemia. 2018;32(8):1768\u201377.","journal-title":"Leukemia."},{"key":"1000_CR11","doi-asserted-by":"crossref","unstructured":"Kuruvilla D, Chia YL, Santiago L, et al. Efficacy and safety of moxetumomab pasudotox (moxe) in adult patients (pts) with relapsed\/refractory Hairy Cell Leukemia (HCL) in relation to drug exposure, baseline disease burden, and immunogenicity [abstract no. 7060]. J Clin Oncol. 2018;36(15 Suppl).","DOI":"10.1200\/JCO.2018.36.15_suppl.7060"},{"key":"1000_CR12","doi-asserted-by":"crossref","unstructured":"Balic K, Standifer N, Santiago L, et al. Pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of Moxetumomab pasudotox (Moxe), an immunotoxin targeting CD22, in adult patients (Pts) with relapsed or refractory Hairy Cell Leukemia (HCL) [abstract no. 7061]. In: 54th annual meeting of the American Society of Clinical Oncology. 2018.","DOI":"10.1200\/JCO.2018.36.15_suppl.7061"},{"issue":"15","key":"1000_CR13","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","volume":"30","author":"RJ Kreitman","year":"2012","unstructured":"Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012;30(15):1822\u20138.","journal-title":"J Clin Oncol."},{"issue":"21","key":"1000_CR14","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2017-09-803072","volume":"131","author":"RJ Kreitman","year":"2018","unstructured":"Kreitman RJ, Tallman MS, Robak T, et al. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood. 2018;131(21):2331\u20134.","journal-title":"Blood."},{"key":"1000_CR15","unstructured":"Kreitman R, Tallman MS, Robak T, et al. Negative minimal residual disease associated with extended response to moxetumomab pasudotox in patients with relapsed\/refractory hairy cell leukemia: long-term follow-up of bone marrow immunohistochemistry analyses from a phase 1 study [abstract no. 2765]. Blood. 2017;130(Suppl 1)."},{"key":"1000_CR16","doi-asserted-by":"crossref","unstructured":"Kreitman RJ, Arons E, Still K, et al. Moxetumomab pasudotox and minimal residual disease in hairy cell leukemia [abstract no. 7079]. J Clin Oncol. 2015;33(15 Suppl).","DOI":"10.1200\/jco.2015.33.15_suppl.7079"}],"updated-by":[{"DOI":"10.1007\/s40265-018-1049-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:00:00Z","timestamp":1546646400000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-1000-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1000-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1000-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T20:24:18Z","timestamp":1571862258000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-1000-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,24]]},"references-count":16,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["1000"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-1000-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-018-1049-5","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,24]]},"assertion":[{"value":"24 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Moxetumomab Pasudotox: First Global Approval, written by Sohita Dhillon, was originally published Online First without open access.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Sohita Dhillon is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}